AcouSort AB (publ) (ACOU.ST)
SEK 4.04
(5.48%)
SEK 4.04
(5.48%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -17.48 Million SEK | -21.87% |
| 2022 | -14.34 Million SEK | -18.06% |
| 2021 | -12.15 Million SEK | -55.54% |
| 2020 | -7.81 Million SEK | 18.99% |
| 2019 | -9.64 Million SEK | -7.52% |
| 2018 | -8.97 Million SEK | -47.74% |
| 2017 | -6.07 Million SEK | -844.32% |
| 2016 | -643 Thousand SEK | -118.0% |
| 2015 | -294.95 Thousand SEK | -317.16% |
| 2014 | 135.82 Thousand SEK | 173.1% |
| 2013 | -185.81 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.67 Million SEK | 20.93% |
| 2024 Q1 | -5.91 Million SEK | 21.26% |
| 2023 Q2 | -3.87 Million SEK | -22.05% |
| 2023 Q4 | -7.51 Million SEK | -82.98% |
| 2023 FY | -22.5 Million SEK | -56.83% |
| 2023 Q3 | -4.1 Million SEK | -5.99% |
| 2023 Q1 | -3.17 Million SEK | 9.31% |
| 2022 FY | -14.34 Million SEK | -18.06% |
| 2022 Q4 | -3.5 Million SEK | 17.04% |
| 2022 Q3 | -4.21 Million SEK | -4.66% |
| 2022 Q2 | -4.03 Million SEK | -55.04% |
| 2022 Q1 | -2.6 Million SEK | 26.51% |
| 2021 Q4 | -3.53 Million SEK | -3.0% |
| 2021 Q1 | -1.76 Million SEK | 45.5% |
| 2021 Q2 | -3.41 Million SEK | -93.04% |
| 2021 Q3 | -3.43 Million SEK | -0.64% |
| 2021 FY | -12.15 Million SEK | -55.54% |
| 2020 Q3 | -2.21 Million SEK | -65.17% |
| 2020 FY | -7.81 Million SEK | 18.99% |
| 2020 Q1 | -1.02 Million SEK | 67.84% |
| 2020 Q2 | -1.33 Million SEK | -30.92% |
| 2020 Q4 | -3.24 Million SEK | -46.79% |
| 2019 Q2 | -3.13 Million SEK | -97.23% |
| 2019 FY | -9.64 Million SEK | -7.52% |
| 2019 Q4 | -3.17 Million SEK | -81.7% |
| 2019 Q3 | -1.74 Million SEK | 44.12% |
| 2019 Q1 | -1.58 Million SEK | 45.84% |
| 2018 Q1 | -2.26 Million SEK | -4.24% |
| 2018 Q4 | -2.93 Million SEK | -38.93% |
| 2018 FY | -8.97 Million SEK | -47.74% |
| 2018 Q3 | -2.1 Million SEK | -26.36% |
| 2018 Q2 | -1.66 Million SEK | 26.25% |
| 2017 Q3 | -1.28 Million SEK | 26.4% |
| 2017 FY | -6.07 Million SEK | -844.32% |
| 2017 Q1 | -864 Thousand SEK | -24.5% |
| 2017 Q2 | -1.75 Million SEK | -102.55% |
| 2017 Q4 | -2.17 Million SEK | -68.56% |
| 2016 Q3 | 134 Thousand SEK | 191.3% |
| 2016 FY | -643 Thousand SEK | -118.0% |
| 2016 Q1 | -117 Thousand SEK | 50.2% |
| 2016 Q4 | -694 Thousand SEK | -617.91% |
| 2016 Q2 | 46 Thousand SEK | 139.32% |
| 2015 Q4 | -234.95 Thousand SEK | -252.57% |
| 2015 Q3 | 154 Thousand SEK | 0.0% |
| 2015 FY | -294.95 Thousand SEK | -317.16% |
| 2014 FY | 135.82 Thousand SEK | 173.1% |
| 2013 FY | -185.81 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -46.48 Million SEK | 62.381% |
| Biovica International AB (publ) | -126.07 Million SEK | 86.129% |
| Cantargia AB (publ) | -290.01 Million SEK | 93.97% |
| CombiGene AB (publ) | -36.3 Million SEK | 51.833% |
| Cyxone AB (publ) | -21.66 Million SEK | 19.27% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -51.193% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -2.285% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 83.497% |
| Fluicell AB (publ) | -26.87 Million SEK | 34.942% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 87.01% |
| Mendus AB (publ) | -100.65 Million SEK | 82.626% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 58.048% |
| I-Tech AB | 24.43 Million SEK | 171.565% |
| Intervacc AB (publ) | -93.57 Million SEK | 81.313% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -41.355% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 197.101% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -6.622% |
| OncoZenge AB (publ) | -15.9 Million SEK | -9.967% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -1969.467% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 94.367% |
| Lipum AB (publ) | -37.25 Million SEK | 53.06% |
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 92.977% |
| Ziccum AB (publ) | -21.56 Million SEK | 18.891% |
| BioArctic AB (publ) | 252.64 Million SEK | 106.922% |
| Genovis AB (publ.) | 54.22 Million SEK | 132.25% |
| Camurus AB (publ) | 532.35 Million SEK | 103.285% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 90.326% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 68.445% |
| Aptahem AB (publ) | -10.1 Million SEK | -73.057% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 94.561% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 90.326% |
| Kancera AB (publ) | -65.04 Million SEK | 73.114% |
| Saniona AB (publ) | -81.06 Million SEK | 78.428% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 58.859% |
| Xintela AB (publ) | -57.23 Million SEK | 69.449% |
| Abliva AB (publ) | -96.54 Million SEK | 81.888% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -398.916% |
| Amniotics AB (publ) | -29.07 Million SEK | 39.851% |
| 2cureX AB (publ) | -36.36 Million SEK | 51.91% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -19.447% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 95.451% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.782% |
| Biosergen AB | -27.26 Million SEK | 35.863% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -12.732% |
| Corline Biomedical AB | -1.78 Million SEK | -878.02% |
| NextCell Pharma AB | -43.17 Million SEK | 59.495% |
| Nanologica AB (publ) | -69.96 Million SEK | 75.005% |
| LIDDS AB (publ) | -40.67 Million SEK | 57.007% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 94.616% |
| BioInvent International AB (publ) | -369.94 Million SEK | 95.273% |
| SynAct Pharma AB | -224.49 Million SEK | 92.211% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 60.415% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 26.998% |
| Alzinova AB (publ) | -16.52 Million SEK | -5.841% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 84.234% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 93.1% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -173.523% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 84.804% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 13.168% |
| Simris Alg AB (publ) | -36.63 Million SEK | 52.267% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 88.069% |